2023-509334-19-00进行中（未招募）3 期
Trial title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)
Rayzebio Inc., Rayzebio Inc.20 个研究点 分布在 4 个国家目标入组 78 人开始时间: 2024年3月12日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 78
- 试验地点
- 20
- 主要终点
- Part 1: - Incidence of DLTs during the first 56 days of study treatment
研究概览
简要总结
Part 1:
- To determine the RP3D of RYZ101
- To assess the safety and tolerability of RYZ101 in subjects with SSTR+ GEP-NET that has progressed following treatment with 177Lu-SSA Part 2:
- To determine if treatment with RYZ101, compared to SoC therapy, improves centrally confirmed PFS in study subjects.
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Part 2: Subject is a candidate for therapy with 1 of the following SoC options: a. Everolimus 10 mg daily by mouth b. Sunitinib 37.5 mg daily by mouth c. High-dose octreotide LAR 60 mg Q4W by intramuscular (i.m.) injection d. High dose frequency lanreotide 120 mg every 2 weeks (Q2W) by deep subcutaneous (s.c.) injection.
- •Adequate renal function, as evidenced by eGFR ≥60 mL/min/1.73 m2(calculated using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation)
- •Adequate hematologic function, defined by the following laboratory results: Part 2: Hemoglobin concentration ≥5.0 mmol/L (≥8.0 g/dL); ANC ≥ 1000 cells/µL (≥1000 cells/mm3); platelets >100x 109/L (100 x 103/mm3).
- •Total bilirubin ≤3 x upper limit normal (ULN)
- •Serum albumin ≥3.0 g/dL unless prothrombin time (PT) is within the normal range
- •For women of childbearing potential (WOCBP): a. Negative serum pregnancy test within 48 hours prior to the first dose of study treatment b. Agreement to use barrier contraception and a second form of highly effective contraception while receiving study treatment and for 7 months following their last dose of study treatment. Alternatively, total abstinence is also considered a highly effective contraception method when this is in line with the preferred and usual lifestyle of the subject. c. A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (≥12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (total hysterectomy, or bilateral tubal ligation or bilateral oophorectomy at least 6 weeks before taking study treatment).
- •Sexually active male subjects must use a condom during intercourse while receiving study treatment and for 4 months after the last dose of the study treatment and should not father a child during this period. a. Male study participants whose sexual partners are WOCBP must also agree to use a second form of highly effective contraception while receiving study treatment and for 4 months following their last dose of RYZ
- •Alternatively, total abstinence is also considered a highly effective contraception method. b. A condom is required to be used also by vasectomized men as well as during intercourse with a male partner to prevent delivery of the drug via seminal fluid.
排除标准
- •Subjects with a GEP-NET deemed nonresponsive to PRRT, defined as no disease control (PR, CR, or SD) achieved for at least 6 months following the last dose of prior 177Lu-DOTATATE/TOC or 177Lu-HA- DOTATATE treatment.
- •PRRT other than 177Lu-DOTATATE/TOC or 177Lu-HA-DOTATATE as described in Inclusion Criterion #7
- •Any condition requiring systemic treatment with high-dose glucocorticoids (≥20 mg prednisone per day or equivalent) within 14 days prior to first dose of study treatment and/or which cannot be stopped while on study (unless solely for the purpose of adrenal replacement). Inhaled or topical steroids and single dose of steroids as pre-medication for CT scans with contrast are permitted.
- •Known hypersensitivity to 225Actinium, 68Gallium, 64Copper, octreotate, or any of the excipients of DOTATATE imaging agents
- •Prior history of liver cirrhosis or liver transplantation.
- •Part 1: Prior treatment with alkylating agents
- •Prior radioembolization
- •Any surgery, chemoembolization, and radiofrequency ablation within 12 weeks prior to first dose of study treatment
- •Use of anticancer agents within the following intervals prior to the first dose of study treatment: a. PRRT: within < 6 months (177Lu-DOTATATE/TOC or 177Lu-HA- DOTATATE only, as described in Inclusion Criterion #7) b. Chemotherapy: within <6 weeks c. Small molecule inhibitors: within <4 weeks d. Biological agents: within 4 weeks
- •Prior radiation therapy as defined below: a. Part 1: Any prior external beam radiation therapy, including stereotactic body radiation therapy (SBRT) b. Part 2: Any of the following: i. Radiation therapy within 6 weeks prior to the first dose of study treatment ii. Prior external beam radiation therapy to more than 25% of the bone marrow
- •Prior participation in any interventional clinical study within 30 days prior to first dose of study treatment
- •Significant cardiovascular disease, such as New York Heart Association (NYHA) Class ≥II heart failure a. Subjects with a known left ventricular ejection fraction (LVEF) <40% will be excluded. b. Subjects with known coronary artery disease, congestive heart failure not meeting the above criteria, or LVEF <50% must be on a stable medical regimen that is optimized in the opinion of the treating physician. c. QT interval corrected for heart rate using Fridericia's formula (QTcF) >470 ms for females and >450 ms for males, demonstrated by the average value of 3 consecutive ECGs
- •Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study
- •Pregnancy or breastfeeding
- •Resistant hypertension, defined as persistent uncontrolled blood pressure (BP) >140/90 mmHg while on optimal doses of at least 3 antihypertensive medications with 1 being a diuretic. Patients with baseline hypertension may be eligible after initiation of antihypertensive therapy.
- •Uncontrolled diabetes mellitus as defined by hemoglobin A1C (HgB A1C) ≥8%
- •Have a history of primary malignancy within the past 3 years other than (1) GEP-NET, (2) adequately treated carcinoma in situ or non-melanoma carcinoma of the skin, (3) any other curatively treated malignancy that is not expected to require treatment for recurrence during participation in the study, or (4) an untreated cancer on active surveillance that may not affect the subject's survival status for ≥3 years based on clinician assessment/statement and with Medical Monitor approval.
- •Known brain, meningeal or spinal cord metastases. In Part 2, subjects with previously treated brain metastases will be allowed if the following conditions are met: (a) there is no evidence of central nervous system (CNS) progression for at least 6 months as assessed by local MRI for brain metastasis during screening; (b) the subject has recovered from acute side effects of radiotherapy; and (c) the subject is receiving a stable or decreasing dose of steroids.
- •For subjects with functional tumors that require treatment with SSAs for symptom control: a. Any subject receiving treatment with short acting octreotide, which cannot be interrupted for 24 hours before the administration of RYZ
- •b. Any subject receiving treatment with octreotide LAR or lanreotide, which cannot be interrupted for at least 4 weeks before the administration of RYZ101.(Note: Long-acting SSAs can be transitioned to short-acting SSAs for these 4 weeks. Long-acting SSAs can be re-started as early as 4 hours after the end of a RYZ101 infusion.)
- •Subject requires other treatment that in the opinion of the investigator would be more appropriate than the therapy offered in the study
- •Unable or unwilling to comply with the requirements of the study protocol
结局指标
主要结局
Part 1: - Incidence of DLTs during the first 56 days of study treatment
Part 1: - Incidence of DLTs during the first 56 days of study treatment
Part 1: Incidence and severity of AEs by NCI CTCAE v5, including SAEs, laboratory changes, ECG changes, and other safety findings
Part 1: Incidence and severity of AEs by NCI CTCAE v5, including SAEs, laboratory changes, ECG changes, and other safety findings
Part 2: - PFS as determined by BICR PFS will be defined as the time from the date of randomization until the date of progression (as determined by BICR from tumor assessments using RECIST v1.1) or death due to any cause, whichever occurs first.
Part 2: - PFS as determined by BICR PFS will be defined as the time from the date of randomization until the date of progression (as determined by BICR from tumor assessments using RECIST v1.1) or death due to any cause, whichever occurs first.
次要结局
- Part 2: - OS will be defined as the time from the date of randomization until the date of death due to any cause.
- ORR, as determined by BICR according to RECIST v1.1
- PFS as determined by the Investigator
- ORR, as assessed by the Investigator according to RECIST v1.1
- BOR, disease control rate (PR + CR + SD), and DoR (only for subjects with a RECIST v1.1 response) assessed by BICR and by the Investigator according to RECIST v1.1
- Incidence and severity of AEs by NCI CTCAE v5, including SAEs, laboratory changes, ECG changes, and other safety findings
- PFS2 as determined by the investigator PFS2 will be defined as the time from randomization to second objective disease progression after subsequent anti-cancer therapy, or death from any cause, whichever first.
- Relationship between biomarkers, including but not limited to CgA in the serum and (5 HIAA) in the urine, with AEs of special interest and/or efficacy endpoints (e.g., PFS, OS, BOR, DoR)
- Changes in: • EQ-5D-5L • EORTC QLQ-C30 and • EORTC QLQ GI NET21 questionnaire scores
- Population predicted exposure parameters (i.e. Cmax, AUC, average concentration)
- Relationship between exposure endpoints and clinical outcomes (efficacy and safety)
- PK parameters, measured by: • Cmax, Tmax, AUC, Vd, clearance, T1/2 • Percentage of radioactivity of the injected parent drug recovered in urine • ECG parameters (including QTc), measured by continuous ECG recording using a 12 lead Holter monitoring device
研究者
RayzeBio Senior Medical Director
Scientific
Rayzebio Inc.
研究点 (20)
Loading locations...
相似试验
招募中
2 期
Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor PatientsNCT07290088Intra-IMMUSG Pte Ltd52
招募中
2 期
A trial to learn how safe AZD4512 is and how it works in the bodies of people with B-cell acute lymphoblastic leukemia (B-ALL)2025-522372-93-00AstraZeneca AB13
尚未招募
1 期
Phase 1 Study of the Safety and Pharmacokinetics of YN001 With Rosuvastatin in Healthy Chinese SubjectsNCT07309042Beijing Inno Medicine Co., Ltd.24
招募中
2 期
A trial to learn how safe AZD3632 is, how well it works, and how it moves throughout the body over time in adults with acute leukemia and myelodysplastic syndrome with HOX gene overexpression2025-521299-76-00AstraZeneca AB1
已完成
2 期
Phase 1/2 Study of Belzutifan Plus Palbociclib Versus Belzutifan in Advanced Renal Cell Carcinoma (RCC)2023-504963-17-00Merck Sharp & Dohme LLC76